Contineum Therapeutics (CTNM) Cash from Investing Activities (2023 - 2026)

Contineum Therapeutics' Cash from Investing Activities history runs 4 years deep, the most recent figure standing at -$39.3 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 363.55% year-over-year to -$39.3 million; the TTM figure through Mar 2026 stood at -$57.9 million (up 8.84% YoY), while the FY2025 annual figure was -$3.7 million, up 94.68% from the prior year.
• Cash from Investing Activities was -$39.3 million for Q1 2026 at Contineum Therapeutics, up from -$47.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $14.9 million in Q3 2025 to a low of -$47.5 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged -$13.7 million across 4 years, with a median of -$9.4 million in 2024.
• Biggest YoY gain for Cash from Investing Activities was 149.5% in 2025; the steepest drop was 405.46% in 2025.
• A 4-year view of Cash from Investing Activities shows it stood at $9.0 million in 2023, then plunged by 203.96% to -$9.4 million in 2024, then tumbled by 405.46% to -$47.5 million in 2025, then gained by 17.16% to -$39.3 million in 2026.
• The last three Cash from Investing Activities figures came in at -$39.3 million (Q1 2026), -$47.5 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.